Literature DB >> 24311407

Four patients with Sillence type I osteogenesis imperfecta and mild bone fragility, complicated by left ventricular cardiac valvular disease and cardiac tissue fragility caused by type I collagen mutations.

Anthony M Vandersteen1, Allan M Lund, David J P Ferguson, Philip Sawle, Rebecca C Pollitt, Susan E Holder, Emma Wakeling, Neil Moat, F Michael Pope.   

Abstract

Osteogenesis imperfecta (OI) type I is a hereditary disorder of connective tissue (HDCT) characterized by blue or gray sclerae, variable short stature, dentinogenesis imperfecta, hearing loss, and recurrent fractures from infancy. We present four examples of OI type I complicated by valvular heart disease and associated with tissue fragility. The diagnosis of a type I collagen disorder was confirmed by abnormal COL1A1 or COL1A2 gene sequencing. One patient was investigated with electrophoresis of collagens from cultured skin fibroblasts, showing structurally abnormal collagen type I, skin biopsy showed unusual histology and abnormal collagen fibril ultra-structure at electron microscopy. The combined clinical, surgical, histological, ultra-structural, and molecular genetic data suggest the type I collagen defect as contributory to cardiac valvular disease. The degree of tissue fragility experienced at cardiac surgery in these individuals, also reported in a small number of similar case reports, suggests that patients with OI type I need careful pre-operative assessment and consideration of the risks and benefits of cardiac surgery.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  mitral valve; osteogenesis imperfecta; tissue fragility

Mesh:

Substances:

Year:  2013        PMID: 24311407     DOI: 10.1002/ajmg.a.36285

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

Review 1.  Bone Disease in Patients with Ehlers-Danlos Syndromes.

Authors:  Shuaa Basalom; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2020-04       Impact factor: 5.096

2.  Genetic analysis of osteogenesis imperfecta in the Palestinian population: molecular screening of 49 affected families.

Authors:  Osama Essawi; Sofie Symoens; Maha Fannana; Mohammad Darwish; Mohammad Farraj; Andy Willaert; Tamer Essawi; Bert Callewaert; Anne De Paepe; Fransiska Malfait; Paul J Coucke
Journal:  Mol Genet Genomic Med       Date:  2017-11-18       Impact factor: 2.183

3.  Osteogenesis imperfecta type III/Ehlers-Danlos overlap syndrome in a Chinese man.

Authors:  Yanqin Lu; Yanzhou Wang; Frank Rauch; Hu Li; Yao Zhang; Naixiang Zhai; Jian Zhang; Xiuzhi Ren; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-02

4.  Mitral Regurgitation and Heart Failure as the First Presentation in a Patient with Features of Two Connective Tissue Disorders: A Rare Combination of Mucopolysaccharidosis and Osteogenesis Imperfecta?

Authors:  Yasuhiro Hamatani; Junko Nakashima; Keiko Ohta-Ogo; Makoto Amaki; Masashi Koga; Daisetsu Aoyama; Kyohei Marume; Kenichiro Sawada; Yasuteru Nakashima; Atsushi Shibata; Atsushi Okada; Hiroyuki Takahama; Takuya Hasegawa; Yasuo Sugano; Hideaki Kanzaki; Yoshihiko Ikeda; Satoshi Yasuda; Hatsue Ishibashi-Ueda; Toshihisa Anzai
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

Review 5.  Ehlers-Danlos syndromes and their manifestations in the visual system.

Authors:  Samuel Asanad; May Bayomi; Douglas Brown; Joshua Buzzard; Eric Lai; Carlthan Ling; Trisha Miglani; Taariq Mohammed; Joby Tsai; Olivia Uddin; Eric Singman
Journal:  Front Med (Lausanne)       Date:  2022-09-27

6.  Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.

Authors:  Ruwan A Weerakkody; Jana Vandrovcova; Christina Kanonidou; Michael Mueller; Piyush Gampawar; Yousef Ibrahim; Penny Norsworthy; Jennifer Biggs; Abdulshakur Abdullah; David Ross; Holly A Black; David Ferguson; Nicholas J Cheshire; Hanadi Kazkaz; Rodney Grahame; Neeti Ghali; Anthony Vandersteen; F Michael Pope; Timothy J Aitman
Journal:  Genet Med       Date:  2016-03-24       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.